TG Therapeutics, Inc.
TGTX
$35.99
-$0.73-1.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.97% | 84.52% | 44.55% | 154.47% | 124.44% |
| Total Depreciation and Amortization | -72.67% | -67.77% | -60.57% | -36.14% | -41.69% |
| Total Amortization of Deferred Charges | -32.55% | -14.79% | 5.43% | 23.90% | 34.63% |
| Total Other Non-Cash Items | 28.89% | 14.16% | -1.29% | -14.13% | 48.97% |
| Change in Net Operating Assets | -143.21% | -29.10% | 5.02% | -141.99% | -130.64% |
| Cash from Operations | -400.88% | -28.98% | 33.24% | 142.32% | 112.12% |
| Capital Expenditure | -- | -- | -700.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 91.36% | 98.04% | -693.24% | -319.23% | -407.13% |
| Cash from Investing | 91.23% | 97.95% | -693.65% | -319.28% | -407.25% |
| Total Debt Issued | -- | 879.26% | 879.26% | -100.00% | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.05% | -98.09% | -99.28% | -98.81% | 5,675.91% |
| Repurchase of Common Stock | -1,488,200.00% | -875,900.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -611.20% | -586.40% | 100.00% | 100.00% |
| Cash from Financing | 157.84% | 76.78% | 85.00% | -99.22% | 84.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 304.22% | 1,029.31% | 9.45% | 71.86% | 111.29% |